Gen­Sight’s sec­ond LHON gene ther­a­py PhI­II stum­bles out of the gate — just like the first time

How­ev­er Gen­Sight’s gene ther­a­py for Leber hered­i­tary op­tic neu­ropa­thy works, it clear­ly has no sig­nif­i­cant ef­fect at 48 weeks. But that doesn’t mean the biotech has lost hope in their drug.

The Paris-based biotech re­port­ed ear­ly Mon­day that GS010 flopped in their Phase III con­fir­ma­to­ry tri­al at 48 weeks, falling far short of the mark re­searchers set for an im­prove­ment in the sight of the treat­ed eye com­pared to the sham ther­a­py of­fered in the oth­er eye. Vi­sion in both eyes de­te­ri­o­rat­ed at al­most ex­act­ly the same rate.

Bernard Gilly

Re­searchers al­so saw a matchup be­tween the ther­a­py and a place­bo in the first Phase III, but the com­pa­ny went on to es­tab­lish a suc­cess­ful read­out for their 72-week da­ta in the first RE­VERSE study — and that’s what they’ll be anx­ious­ly hop­ing to see in this study. An­oth­er eval­u­a­tion at 96-weeks will be used to cap the study with close to 2 years of mon­i­tor­ing time.

The lat­est 48-week da­ta al­so high­light­ed two oth­er key fail­ures: change from base­line of tem­po­ral reti­nal nerve fiber lay­er missed sta­tis­ti­cal sig­nif­i­cance as well as pa­pil­lo-mac­u­lar bun­dle thick­ness and gan­glion cell vol­ume. But the in­ves­ti­ga­tors spot­light­ed oth­er trends that they say were pos­i­tive in­di­ca­tors — not un­usu­al for a failed read­out.

Gen­Sight may have been ready with an ex­pla­na­tion, but not all in­vestors were con­tent to see the sec­ond tri­al get start­ed with an­oth­er set­back at 48 weeks. The biotech’s stock {$SIGHT on the Paris ex­change) tum­bled 19%.

It’s just a mat­ter of time for the ther­a­py to start work­ing, the biotech cau­tioned. And they’ll con­tin­ue to push reg­u­la­tors for a quick ap­proval of the gene ther­a­py for a rare mi­to­chon­dr­i­al dis­ease that de­stroys vi­sion.

José-Alain Sa­hel

“The pow­er­ful and rapid de­gen­er­a­tion of neu­rons ear­ly in the dis­ease, com­bined with the time need­ed for GS010 to cause func­tion­ing pro­teins to be ex­pressed, may be con­found­ing ef­fi­ca­cy mea­sure­ments ear­ly in the ac­tive pro­gres­sion phase,” not­ed the Sor­bonne’s José-Alain Sa­hel, di­rec­tor of the In­sti­tut de la Vi­sion.

“As ex­pect­ed, the RES­CUE re­sults at Week 48 present a more com­plex pic­ture be­cause of the in­tense, bru­tal and ex­treme­ly rapid on­set of the reti­nal gan­glion cells’ de­gen­er­a­tion.” said Bernard Gilly, co-founder and CEO of Gen­Sight. “But as with RE­VERSE, lat­er read­outs are like­ly to con­firm our con­fi­dence in the ef­fi­ca­cy of GS010.”

Norbert Bischofberger. Kronos

Backed by some of the biggest names in biotech, Nor­bert Bischof­berg­er gets his megaround for plat­form tech out of MIT

A little over a year ago when I reported on Norbert Bischofberger’s jump from the CSO job at giant Gilead to a tiny upstart called Kronos, I noted that with his connections in biotech finance, that $18 million launch round he was starting off with could just as easily have been $100 million or more.

With his first anniversary now behind him, Bischofberger has that mega-round in the bank.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Novotech CRO Ex­pands Chi­na Team as Biotech De­mand for Clin­i­cal Tri­als In­creas­es up to 79%

An increase in demand of up to 79% for clinical trials in China has prompted Novotech the Asia-Pacific CRO to rapidly expand the China team, appointing expert local clinical executives to their Shanghai and Hong Kong offices. The company is planning to expand their team by 30% over the next quarter.

Novotech China has seen considerable demand recently which is borne out by research from GlobalData:
A global migration of clinical research is occurring from high-income countries to low and middle-income countries with emerging economies. Over the period 2017 to 2018, for example, the number of clinical trial sites opened by biotech companies in Asia-Pacific increased by 35% compared to 8% in the rest of the world, with growth as high as 79% in China.
Novotech CEO Dr John Moller said China offers the largest population in the world, rapid economic growth, and an increasing willingness by government to invest in research and development.
Novotech’s 23 years of experience working in the region means we are the ideal CRO partner for USA biotechs wanting to tap the research expertise and opportunities that China offers.
There are over 22,000 active investigators in Greater China, with about 5,000 investigators with experience on at least 3 studies (source GlobalData).

On a glob­al romp, Boehringer BD team picks up its third R&D al­liance for Ju­ly — this time fo­cused on IPF with $50M up­front

Boehringer Ingelheim’s BD team is on a global deal spree. The German pharma company just wrapped its third deal in 3 weeks, going back to Korea for its latest pipeline pact — this time focused on idiopathic pulmonary fibrosis.

They’re handing over $50 million to get their hands on BBT-877, an ATX inhibitor from Korea’s Bridge Biotherapeutics that was on display at a science conference in Dallas recently. There’s not a whole lot of data to evaluate the prospects here.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.

Servi­er scoots out of an­oth­er col­lab­o­ra­tion with Macro­Gen­ics, writ­ing off their $40M

Servier is walking out on a partnership with MacroGenics $MGNX — for the second time.

After the market closed on Wednesday MacroGenics put out word that Servier is severing a deal — inked close to 7 years ago — to collaborate on the development of flotetuzumab and other Dual-Affinity Re-Targeting (DART) drugs in its pipeline.

MacroGenics CEO Scott Koenig shrugged off the departure of Servier, which paid $20 million to kick off the alliance and $20 million to option flotetuzumab — putting a heavily back-ended $1 billion-plus in additional biobuck money on the table for the anti-CD123/CD3 bispecific and its companion therapies.

Den­mark's Gen­mab hits the jack­pot with $500M+ US IPO as small­er biotechs rake in a com­bined $147M

Danish drugmaker Genmab A/S is off to the races with perhaps one of the biggest biotech public listings in decades, having reaped over $500 million on the Nasdaq, as it positions itself as a bonafide player in antibody-based cancer therapies.

The company, which has long served as J&J’s $JNJ key partner on the blockbuster multiple myeloma therapy Darzalex, has asserted it has been looking to launch its own proprietary product — one it owns at least half of — by 2025.

FDA over­rides ad­comm opin­ions a fifth of the time, study finds — but why?

For drugmakers, FDA advisory panels are often an apprehended barometer of regulators’ final decisions. While the experts’ endorsement or criticism often translate directly to final outcomes, the FDA sometimes stun observers by diverging from recommendations.

A new paper out of Milbank Quarterly put a number on that trend by analyzing 376 voting meetings and subsequent actions from 2008 through 2015, confirming the general impression that regulators tend to agree with the adcomms most of the time — with discordances in only 22% of the cases.

UP­DAT­ED: With loom­ing ‘apoc­a­lypse of drug re­sis­tance,’ Mer­ck’s com­bi­na­tion an­tibi­ot­ic scores FDA ap­proval on two fronts

Merck — one of the last large biopharmaceuticals companies in the beleaguered field of antibiotic drug development — on Wednesday said the FDA had sanctioned the approval of its combination antibacterial for the treatment of complicated urinary tract and intra-abdominal infections.

To curb the rise of drug-resistant bacteria and maintain the efficacy of the therapy, Recarbrio (and other antibacterials) — the drug must be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible gram-negative bacteria, Merck $MRK said.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.